Michael H Gold1, Michael McGuire, Thomas A Mustoe, Andrea Pusic, Mukta Sachdev, Jill Waibel, Crystal Murcia. 1. *Gold Skin Care Center and Tennessee Clinical Research Center, Nashville, Tennessee; †University of California, Los Angeles, Los Angeles, California; ‡The University of Southern California, Los Angeles, CA; §Division of Plastic and Reconstructive Surgery, Northwestern University, Chicago, Illinois; ‖Memorial Sloan-Kettering Cancer Center, New York, New York; ¶Department of Dermatology, Manipal Hospital, Bangalore, India; #Miami Dermatology and Laser Institute, Miami, Florida; **Inkwell Medical Communications, Novelty, Ohio.
Abstract
BACKGROUND: In 2002, an international advisory panel was convened to assess the scientific literature and develop evidence-based guidance for the prevention and treatment of pathologic scarring. Emerging clinical data, new treatment options, and technical advances warranted a renewed literature search and review of the initial advisory panel recommendations. OBJECTIVE: To update the management algorithm for pathologic scarring to reflect best practice standards at present. MATERIALS AND METHODS: Management recommendations were derived from clinical evidence amassed during a comprehensive literature search and from the clinical experience and consensus opinion of advisory panel members. RESULTS: A combination approach using multiple modalities provides the maximum potential for successful treatment of hypertrophic scars and keloids. The advisory panel advocates a move toward more aggressive initial management of keloids, including earlier application of 5-fluorouracil. A growing body of clinical research supports a place in therapy for newer agents (e.g., bleomycin, onion extract, imiquimod, mitomycin C) and laser therapy (pulsed-dye, fractional) for scar management. CONCLUSION: Prevention and treatment of pathologic scarring requires individualized care built upon the principles of evidence-based medicine and continues to evolve in step with technological and scientific advances.
BACKGROUND: In 2002, an international advisory panel was convened to assess the scientific literature and develop evidence-based guidance for the prevention and treatment of pathologic scarring. Emerging clinical data, new treatment options, and technical advances warranted a renewed literature search and review of the initial advisory panel recommendations. OBJECTIVE: To update the management algorithm for pathologic scarring to reflect best practice standards at present. MATERIALS AND METHODS: Management recommendations were derived from clinical evidence amassed during a comprehensive literature search and from the clinical experience and consensus opinion of advisory panel members. RESULTS: A combination approach using multiple modalities provides the maximum potential for successful treatment of hypertrophic scars and keloids. The advisory panel advocates a move toward more aggressive initial management of keloids, including earlier application of 5-fluorouracil. A growing body of clinical research supports a place in therapy for newer agents (e.g., bleomycin, onion extract, imiquimod, mitomycin C) and laser therapy (pulsed-dye, fractional) for scar management. CONCLUSION: Prevention and treatment of pathologic scarring requires individualized care built upon the principles of evidence-based medicine and continues to evolve in step with technological and scientific advances.
Authors: Joong Min Suh; Seong Hoon Park; Jun Won Lee; Seong Joo Lee; In Suck Suh; Jong Wook Lee; Hii Sun Jeong Journal: Aesthetic Plast Surg Date: 2021-05-10 Impact factor: 2.326